A split-face, randomized, double-blind study in the journal Plastic and Reconstructive Surgery found that Botox and Xeomin, or incobotulinumtoxinA, which was recently approved by the FDA, performed similarly at identical dosages in reducing glabellar lines, crow’s feet and forehead lines. Botox, however, performed better at three days, two weeks, three months and four months when dosages were not identical and were instead determined based on studies, peer discussion and physician experience.
Cleveland, Tenn., doctor Raymond Sean Brown is facing health care fraud charges, accused of falsely billing Medicare and receiving $7.5 million in reimbursements. Brown bought 254 vials of non-FDA-approved Botox, but submitted billings to Medicare for 17,766 Botox injections, authorities claim. Brown also faces charges of money laundering, mail and wire fraud, although his lawyer maintains that Brown is not guilty.
People should view palliative care as a "collection of medical interventions that make serious illness and/or the process of dying less excruciating," rather than as "giving up," author Heather Millar writes in a WebMD blog. Millar writes about her parents' reluctance to talk about end-of-life preferences and notes that palliative care should be discussed with patients facing any serious illness.
Johnson & Johnson expects to receive FDA approval next year for a wrinkle-reducing injection similar to Allergan's Botox. Allergan already faces competition from Valeant's Dysport and Merz's Xeomin, but it has an 85% market share.
Injecting tiny amounts of Botox in points around the eyebrows yielded natural-looking results that avoided forehead paralysis or upper eyelid or eyebrow ptosis, a five-year study found. The lead investigator says he would like to license the technique.